DR. WILLIAM PAUL PETERS, MD, PH.D
Osteopathic Medicine at 14 St, Fernandina, FL
License number
Florida ME96619
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
1551 S 14Th St SUITE D, Fernandina, FL 32034
2234 Colonial Blvd Attn: Managed Care Dept., Fort Myers, FL 33907
2234 Colonial Blvd Attn: Managed Care Dept., Fort Myers, FL 33907
Phone
(904) 493-5100
(904) 277-9738 (Fax)
(239) 931-7342
(239) 931-7385 (Fax)
(904) 277-9738 (Fax)
(239) 931-7342
(239) 931-7385 (Fax)
Personal information
See more information about WILLIAM PAUL PETERS at radaris.comName
Address
Phone
5048 Cape Romain Ct, Jacksonville, FL 32277
5165 N Sacramento Ave, Beverly Hills, FL 34465
507 Summerfield Way, Venice, FL 34292
4748 61St Way N, Kenneth City, FL 33709
4666 Secret River Trl, Pt Orange, FL 32129
Professional information
See more information about WILLIAM PAUL PETERS at trustoria.com
Dr. William P Peters, Amelia Island FL - MD (Doctor of Medicine)
Dr. William P Peters, Amelia Island FL - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
1551 S 14Th St SUITE D, Amelia Island 32034
(904) 493-5100 (Phone)
(904) 493-5100 (Phone)
Procedures:
Breast Cancer
Conditions:
Breast Cancer, Breast Cancer Stages: 0, I, Ii, Iii, Iv, Hematology, Oncology
Certifications:
Internal Medicine, 1981, Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1551 S 14Th St SUITE D, Amelia Island 32034
Baptist Medical Center
800 Prudential Dr, Jacksonville 32207
Baptist Medical Center Nassau
1250 South 18Th St, Fernandina Beach 32034
Baptist Medical Center
800 Prudential Dr, Jacksonville 32207
Baptist Medical Center Nassau
1250 South 18Th St, Fernandina Beach 32034
Education:
Medical School
Columbia University College Of Physicians and Surgeons
Graduated: 1978
Columbia University College Of Physicians and Surgeons
Graduated: 1978
Chemically Modified Cyclic Peptides Containing Cell Adhesion Recognition (Car) Sequences And Uses Therefor
Chemically Modified Cyclic Peptides Containing Cell Adhesion Recognition (Car) Sequences And Uses Therefor
US Patent:
2009013, May 21, 2009
Filed:
Jun 13, 2008
Appl. No.:
12/139270
Inventors:
Mukur Gupta - Morrisville NC, US
Brian Huber - Durham NC, US
William Paul Peters - Fernandina Beach FL, US
Brian Huber - Durham NC, US
William Paul Peters - Fernandina Beach FL, US
Assignee:
ADHEREX TECHNOLOGIES, INC. - Ottawa
International Classification:
A61K 38/16, C07K 14/00, A61P 35/00
US Classification:
514 11, 530317
Abstract:
Chemically modified cyclic peptides comprising cell adhesion recognition (CAR) sequences are provided having improved properties, such as improved stability. Also provided are methods of making and using same.
William Paul Peters, Fernandina Beach FL
William Paul Peters, Fernandina Beach FL
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
First Coast Oncology - Amelia Island
1340 South 18Th St SUITE 103, Fernandina Beach, FL 32034
1340 South 18Th St SUITE 103, Fernandina Beach, FL 32034
Education:
Columbia University (1978)
William Paul Peters, Amelia Island FL
William Paul Peters, Amelia Island FL
Specialties:
Internist
Address:
1551 S 14Th St, Amelia Island, FL 32034
Methods For Administering Dpd Inhibitors In Combination With 5-Fu And 5-Fu Prodrugs
Methods For Administering Dpd Inhibitors In Combination With 5-Fu And 5-Fu Prodrugs
US Patent:
2008025, Oct 16, 2008
Filed:
Feb 6, 2008
Appl. No.:
12/027064
Inventors:
William Paul Peters - Fernandina Beach FL, US
Mukur Gupta - Morrisville NC, US
Mukur Gupta - Morrisville NC, US
Assignee:
ADHEREX TECHNOLOGIES, INC. - Ottawa
International Classification:
A61K 31/505, A61P 17/00
US Classification:
514274
Abstract:
Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient. Also provided are topical formulations comprising DPD, TP and/or UP inhibitors and methods of using same.
Cancer Treatment Methods Using Cadherin Antagonists In Combination With Anticancer Agents
Cancer Treatment Methods Using Cadherin Antagonists In Combination With Anticancer Agents
US Patent:
2008019, Aug 14, 2008
Filed:
Sep 27, 2007
Appl. No.:
11/863127
Inventors:
William Paul Peters - Fernandina Beach FL, US
Brian Huber - Durham NC, US
Douglas Scott Tyler - Hillsborough NC, US
Brian Huber - Durham NC, US
Douglas Scott Tyler - Hillsborough NC, US
Assignee:
ADHEREX TECHNOLOGIES, INC. - Ottawa
DEPARTMENT OF VETERANS AFFAIRS - Washington DC
DEPARTMENT OF VETERANS AFFAIRS - Washington DC
International Classification:
A61K 38/12, A61K 31/197, A61P 35/00
US Classification:
514 9, 514564, 514 2
Abstract:
Improved methods for treating cancer which employ combinations comprising cadherin antagonists with certain anticancer agents or treatments are provided. The methods of the invention involve the administration of cadherin antagonist before, concurrent with, or after, administration of an anticancer agent or treatment and provide unexpectedly improved therapeutic benefit in the treatment of tumors growing in vivo.
Methods For Administering Dpd Inhibitors In Combination With 5-Fu And 5-Fu Prodrugs
Methods For Administering Dpd Inhibitors In Combination With 5-Fu And 5-Fu Prodrugs
US Patent:
2013018, Jul 18, 2013
Filed:
Nov 27, 2012
Appl. No.:
13/686240
Inventors:
Thomas Spector - Durham NC, US
William Paul Peters - Fernandina Beach FL, US
Donald W. Kufe - Wellesley MA, US
Brian Huber - Durham NC, US
William Paul Peters - Fernandina Beach FL, US
Donald W. Kufe - Wellesley MA, US
Brian Huber - Durham NC, US
International Classification:
A61K 31/513
US Classification:
514 51, 514274, 514 50, 514 49
Abstract:
Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
Compositions Comprising Topical Dpd Inhibitors And Methods Of Using Same In The Treatment Of Hand-Foot Syndrome
Compositions Comprising Topical Dpd Inhibitors And Methods Of Using Same In The Treatment Of Hand-Foot Syndrome
US Patent:
2009019, Aug 6, 2009
Filed:
Feb 6, 2009
Appl. No.:
12/367367
Inventors:
William Paul Peters - Fernandina Beach FL, US
Mukur Gupta - Morrisville NC, US
Mukur Gupta - Morrisville NC, US
Assignee:
ADHEREX TECHNOLOGIES INC. - Ottawa
International Classification:
A61K 9/12, A61K 31/513
US Classification:
424 45, 514274
Abstract:
Topical formulations comprising inhibitors of dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and/or uridine phosphorylase (UP) enzyme inhibitors are provided for the treatment of hand-foot syndrome (HFS) in cancer patients undergoing treatment with 5-FU and 5-FU prodrugs.
Methods For Administering Dpd Inhibitors In Combination With 5-Fu And 5-Fu Prodrugs
Methods For Administering Dpd Inhibitors In Combination With 5-Fu And 5-Fu Prodrugs
US Patent:
8318756, Nov 27, 2012
Filed:
Dec 5, 2005
Appl. No.:
11/294643
Inventors:
Thomas Spector - Durham NC, US
William Paul Peters - Fernandina Beach FL, US
Donald W. Kufe - Wellesley MA, US
Brian Huber - Durham NC, US
William Paul Peters - Fernandina Beach FL, US
Donald W. Kufe - Wellesley MA, US
Brian Huber - Durham NC, US
Assignee:
Adherex Technologies, Inc. - Ottawa
International Classification:
A61K 31/505
US Classification:
514274, 514 49, 514 50, 514256, 536 282, 536 2854, 544309, 544313
Abstract:
Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.